Comparing Platform Technologies to Position Multi- Mechanism Cell Therapies in Autoimmune Disease
1:30 pm - Thursday 3rd December 2026
- Comparing non-genetically engineered platforms with CAR-T, in vivo approaches, and other modalities to clarify positioning and differentiation
- Evaluating multi-mechanism activity versus singletarget approaches to improve safety and efficacy outcomes in inflammatory disease
- Exploring translational strategies to extend oncologyderived platforms into autoimmune indications including targeting senescent cells
